| 06/29/2026 13:00 |
Corporate Governance Report |
| 06/24/2026 17:00 |
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 06/24/2026 16:00 |
Notice Regarding Actions to Achieve Management Conscious of Capital Costs and Stock Prices |
| 06/19/2026 14:00 |
Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19 |
| 06/18/2026 13:00 |
Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis |
| 06/01/2026 17:15 |
(Corrections) Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure |
| 06/01/2026 09:20 |
Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure |
| 05/29/2026 15:00 |
Notice Regarding Approval of Naldemedine for Opioid-Induced Constipation in China |
| 05/12/2026 15:30 |
Financial Results for FY2025 Supplement |
| 05/12/2026 15:30 |
Fiscal 2025 Financial Results |
| 05/12/2026 15:30 |
Consolidated Financial Results for Fiscal Year 2025(IFRS) |
| 04/27/2026 17:00 |
Notice Regarding the Absorption-Type Merger of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary |
| 04/27/2026 15:15 |
Notice of Revisions to Dividend Forecasts (Dividend Increase) |
| 04/02/2026 08:30 |
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) |
| 04/01/2026 15:00 |
GSK, Pfizer and Shionogi complete changes to ViiV Healthcare shareholding |
| 03/27/2026 15:30 |
Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd |
| 03/24/2026 08:30 |
Notice Regarding the Consolidation of Shionogi Apnimed Sleep Science, LLC as a Subsidiary of Shionogi |
| 03/23/2026 15:00 |
Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA(Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19 |
| 02/27/2026 13:00 |
Application for Manufacturing and Marketing Approval of a New Lotion Formulation for the Atopic Dermatitis Treatment "CORECTIM" in Japan |
| 02/20/2026 16:30 |
Notice Regarding the Determination of the Basic Policy for the Absorption-Type Merger of TORII PHARMACEUTICAL Co., Ltd. |
| 01/30/2026 13:00 |
Consolidated Financial Results for the Third Quarter of Fiscal Year 2025 (IFRS) |
| 01/30/2026 13:00 |
Financial Results for the 3rd Quarter of FY2025 Supplement |
| 01/30/2026 13:00 |
3rd Quarter of Fiscal 2025 Financial Results |
| 01/20/2026 16:00 |
[Summary]GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding |
| 12/22/2025 15:00 |
Shionogi Receives Approval in Japan to Manufacture and Market ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder |
| 11/28/2025 19:00 |
(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the Second Quarter of Fiscal Year 2025 (IFRS) |
| 10/28/2025 11:00 |
Corporate Governance Report |
| 10/27/2025 16:30 |
Action to Implement Management that is Conscious of Cost of Capital and Stock Price |
| 10/27/2025 15:30 |
Consolidated Financial Results for the second Quarter of Fiscal Year 2025 (IFRS) |
| 10/27/2025 15:30 |
Supplemental material for financial results for the 2nd quarter |
| 10/27/2025 15:30 |
2nd Quarter of Fiscal 2025 Financial Results |
| 10/27/2025 15:30 |
Notice Regarding Absorption-type merger of Shionogi Pharma Co., Ltd. |
| 09/25/2025 15:30 |
Notice Regarding the Execution of an Absorption-Type Company Split Agreement (Simplified Absorption-Type Split) for the Succession of Business |
| 09/01/2025 15:30 |
Notice of Acquisition of TORII PHARMACEUTICAL CO., LTD. as a Wholly-Owned Subsidiary |
| 07/28/2025 15:30 |
Supplemental material for financial results for the 1st quarter of fiscal year 2025 |
| 07/28/2025 15:30 |
Consolidated Financial Results for the First Quarter of Fiscal Year 2025 (IFRS) |
| 07/28/2025 15:30 |
1st Quarter of Fiscal 2025 Financial Results |
| 07/17/2025 15:30 |
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
